New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall a

Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamabResults presented at t...

Related Keywords

Denmark ,Japan ,San Diego ,California ,United States ,Copenhagen ,Køavn ,Netherlands ,Paris ,France General ,France ,New Jersey ,Tokyo ,American ,Andrew Carlsen ,Hematol Hemoter ,Catherine Thieblemont ,David Freundel ,Twitter ,Abbvie Biotechnology Ltd ,Global Communications Corporate Affairs ,Genmab Us Inc ,Lymphoma Research Foundation ,American Society Of Hematology ,Exposition Of The American Society Hematology ,Data From The Observational National Lymphocare Study ,Paris University ,Exchange Commission ,American Society ,Annual Meeting ,Saint Louis Assistance Publique Hopitaux De Paris ,Chief Executive Officer ,Follicular Lymphoma ,Full Prescribing Information ,Medication Guide ,Media Release ,Annual Report ,Y Shaped Genmab ,Abbvie Biotechnology ,Opin Med ,Bras Hematol ,Subsequent Therapy ,Data From ,Observational National Lymphocare ,Treatment Patterns ,Patients With Diffuse Largeb Cell Lymphoma ,Senior Director ,Global Communications ,Corporate Affairs ,Vice President ,Investor Relations ,